Abstract
Non-small cell lung cancer (NSCLC) is known to be a difficult cancer to treat because of its poor prognosis, limited option for surgery, and resistance to chemo or radiotherapy. In this study, we have demonstrated that suppression of rictor expression in A549 and H1299 NSCLC cells by mahanine, a carbazole alkaloid, disrupted constitutive activation of mTOR and Akt. Mahanine suppression of rictor gene expression and consequent attenuation of its protein expression affected the inhibition of mTOR (Ser-2481) and Akt (Ser-473) phosphorylation. Since mahanine treatment revealed this new insight of rictor-mTOR relationship, we examined an association between mTOR activation with rictor expression. Interestingly, in rictor knockdown (KD) NSCLC cells, mTOR activation was significantly impaired. Transfection of rictor over-expression vector into the NSCLC cells reversed this situation. In fact, both rictor KD and mahanine treated cells showed considerably depleted phospho-mTOR level. These results indicate that rictor is required to maintain constitutive activation of mTOR in lung cancer cells. When mTOR kinase activity in rictor KD cells was examined with Akt as substrate, a significant reduction of Akt phosphorylation indicated impairment of mTOR kinase potentiality. Disruption of mTOR and Akt activation caused drastic mortality of NSCLC cancer cells through apoptosis. Hence, our study reveals a new dimension in mTOR-rictor relationship, where rictor stands to be a suitable therapeutic target for lung cancer.
Similar content being viewed by others
Abbreviations
- NSCLC:
-
Non-small cell lung cancer
- Rictor:
-
Rapamycin insensitive companion of mTOR
- mTOR:
-
Mammalian target of rapamycin
- mTORC2:
-
Mammalian target of rapamycin complex 2
- KD:
-
Knock down
- p-Akt:
-
Phosphorylated Akt
- PDK-1:
-
PI3K-dependent kinase-1
- DMEM:
-
Dulbecco’s-modified Eagle’s medium
- FBS:
-
Fetal bovine serum
- DMSO:
-
Dimethyl sulfoxide
- ASO:
-
Antisense oligonucleotide
- Q-PCR:
-
Quantitative PCR
- FITC:
-
Fluorescein isothiocyanate
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2-5- diphenyltetrazolium bromide
- PBS:
-
Phosphate-buffered saline
- Fhit:
-
Fragile histidine triad
References
Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, Akmaev V, Cook B, Dufault M, Zhang M, Zhang W, Guo MZ, Curran J, Han S, Sidransky D, Buetow K, Madden SL, Jen J (2001) Molecular characteristics of non-small cell lung cancer. PNAS 98:15203–15208. doi:10.1073/pnas.261414598
Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/Protein Kinase B is constitutively active in non small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986–3997
Keum JS, Kong G, Yang SC, Shin DH, Park SS, Lee JH, Lee JD (1999) Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 81:127–132
Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H (2000) Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 60:242–244
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L (2000) Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60:4000–4004
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancer. Science 253:49–53
Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y (2000) p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res 6:526–530
Gazzeri S, Gouyer V, Vour’ch C, Brambilla C, Brambilla E (1998) Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 16:497–504
Jagadeesh S, Sinha S, Pal BC, Bhattacharya S, Banerjee PP (2007) Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochem Biophys Res Commun 362:212–217
Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, Mao L (1999) Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 59:4798–4803
Balsara BR, Pei J, Mitsuuchi Y, Page R, Szanto AK, Wang H, Unger M, Joseph R (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25:2053–2059
Nakashio A, Naoya F, Rokudai S, Sato S, Tsuruo T (2000) Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60:5303–5309
Hill MM, Hemmings BA (2002) Inhibition of protein kinase B/Akt: implications for cancer therapy. Pharmacol Ther 93:243–251. doi:10.1016/S0163-7258(02)00193-6
Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G (2003) Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316–2326
Vanhaesebroeck B, Alessi DR (2002) The PI3K–PDK1 connection: more than just a road to PKB. Biochem J 346:561–576
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101
Tang JM, He QY, Guo RX, Chang XJ (2005) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51:181–191
Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL (2007) PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non small cell lung cancer. Oncol Rep 17:853–857
Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-ser 2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69:1821–1827. doi:10.1158/0008-5472.CAN-08-3014
Tyagi P, Belani CP, Jain VK (2005) Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the spirit I and spirit II trials. Clin Lung Cancer 7:17–19
Sinha S, Pal BC, Jagadeesh S, Banerjee PP, Bandyopadhaya A, Bhattacharya S (2006) Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspase. Prostate 66:1257–1265
Seal S, Chatterjee P, Bhattacharya S, Pal D, Dasgupta S, Kundu R, Mukherjee S, Bhattacharya S, Bhuyan M, Bhattacharyya PR, Baishya G, Barua NC, Baruah PK, Rao PG, Bhattacharya S (2012) Vapor of volatile oils from Litsea cubeba seed induces apoptosis and causes cell cycle arrest in lung cancer cells. PLoS One 7(10):e47014. doi:10.1371/journal.pone.0047014 Epub 2012 Oct 16
Chatterjee P, Seal S, Mukherjee S, Kundu R, Mukherjee S, Ray S, Mukhopadhyay S, Majumdar SS, Bhattacharya S (2013) Adipocyte Fetuin-A contributes to macrophage migration into adipose tissue and polarization of macrophages. J Biol Chem 288(39):28324–28330. doi:10.1074/jbc.C113.495473 Epub 2013 Aug 13
Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB (2000) Phosphorylation and inactivation of glycogen synthase kinase by protein kinase A. PNAS 97(22):11960–11965
Pei H, Li L, Fridly BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L (2009) FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16:259–266. doi:10.1016/j.ccr.2009.07.016
Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor is a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302
Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCa, but not S6K1. Dev Cell 11:859–871. doi:10.1016/j.devcel.2006.10.007
Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15(2):148–159. doi:10.1016/j.ccr.2008.12.017
Triens C, Warne PH, Magnuson MA, Pende M, Downward J (2010) Rictor is a novel target of p70S6 kinase-1. Oncogene 29:1003–1016. doi:10.1038/onc.2009.401
Sparks CA, Guertin DA (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29(26):3733–3744. doi:10.1038/onc.2010.139
Acknowledgments
We thank Dr. Partha P. Banerjee (Georgetown University Medical Center, Washington, DC, USA) for providing the A549 cell line and Dr. Susanta Roychoudhury, Cancer Biology Division, CSIR-IICB, Kolkata for H1299 cell line. This research work was financially supported by the grant from CSIR-NEEP Project (HCP-005) and Department of Science and Technology, New Delhi (VI-D&P/289/08-09/TDT). SB expresses his gratitude to NASI, Allahabad for the award of Senior Scientist fellowship. The technical help from Mr. Hemanta Jadav and Mr. Kali Charan Nayek of Visva-Bharati is greatly appreciated.
Conflict of interest
The authors declare that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Priyajit Chatterjee and Soma Seal have equally contributed to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chatterjee, P., Seal, S., Mukherjee, S. et al. A carbazole alkaloid deactivates mTOR through the suppression of rictor and that induces apoptosis in lung cancer cells. Mol Cell Biochem 405, 149–158 (2015). https://doi.org/10.1007/s11010-015-2406-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-015-2406-2